Key result
Vasonatrin, a synthetic hybrid of C-type and atrial natriuretic peptides, displayed intermediate natriuretic and venorelaxant activity while uniquely acting as an arterial vasorelaxant.
Answers are grounded in this paper and cite their sources.
Synthetic hybrid natriuretic peptides like vasonatrin offer the potential to design novel therapies with unique, tailored cardiovascular and renal activity profiles.
The natriuretic peptides continue to amaze researchers in the field with their diversity of biological activity, ranging from reduction ofblood pressure through regulation ofrenal tubular sodium handling to modulation ofneuronal activity in the cen- tral nervous system (1).The article by Wei et al. (2) in the present issue of the Journal would suggest that even now we do not completely understand, nor have we fully exploited, all of the biological properties that these peptides have at their disposal.
No takes yet. Share an insight, caveat, or question.
D. G. Gardner (1993) conducted an editorial in Cardiovascular and renal function. Vasonatrin (synthetic hybrid natriuretic peptide) vs. ANP and CNP was evaluated. Vasonatrin, a synthetic hybrid of C-type and atrial natriuretic peptides, displayed intermediate natriuretic and venorelaxant activity while uniquely acting as an arterial vasorelaxant.
Synapse has enriched 10 related papers. Consider them for comparative context: